Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PHASE 1-2 STUDY EVALUATING HIGH DOSE ADXS11-001 (1 x 10^10 CFU) TREATMENT IN WOMEN WITH HPV+ CARCINOMA OF THE CERVIX

Trial Profile

PHASE 1-2 STUDY EVALUATING HIGH DOSE ADXS11-001 (1 x 10^10 CFU) TREATMENT IN WOMEN WITH HPV+ CARCINOMA OF THE CERVIX

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 07 Mar 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Axalimogene filolisbac (Primary)
  • Indications Adenocarcinoma; Cervical cancer; Squamous cell cancer
  • Focus Adverse reactions
  • Sponsors Advaxis
  • Most Recent Events

    • 04 Mar 2019 Status changed from active, no longer recruiting to completed.
    • 15 May 2017 According to an Advaxis media release, Sharad Ghamande from Georgia Cancer Center at Augusta University is the principal investigator of this trial.
    • 27 Mar 2017 According to an Advaxis media release, one patient from this trial was featured in the Augusta Chronicle.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top